Literature DB >> 23571802

[PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013].

T Wiegel1, P Albers, R Bussar-Maatz, A Gottberg, M Härter, M Kieser, G Kristiansen, G Nettekoven, P Martus, H Schmidberger, S Wellek, M Stöckle.   

Abstract

The PREFERE study is a multicenter randomized study of patients with low or early intermediate risk for prostatic cancer. The four treatment options, radical prostatectomy, percutaneous irradiation therapy, permanent seed implantation and active surveillance recommended by the German S3 guidelines and international guidelines will be tested and compared with respect to effectiveness and potential side effects. Over a period of 4 years a total of 7,600 patients are to be recruited and assigned to 1 of these 4 therapy forms according to personal preference (by possible exclusion of 1 or 2 therapy options) in a 2-4 arm study design by randomization.

Entities:  

Mesh:

Year:  2013        PMID: 23571802     DOI: 10.1007/s00120-013-3186-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  5 in total

1.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

2.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

3.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

Review 4.  Impact of participant and physician intervention preferences on randomized trials: a systematic review.

Authors:  Michael King; Irwin Nazareth; Fiona Lampe; Peter Bower; Martin Chandler; Maria Morou; Bonnie Sibbald; Rosalind Lai
Journal:  JAMA       Date:  2005-03-02       Impact factor: 56.272

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

  5 in total
  7 in total

1.  [Indicator analysis of prostate cancer centers certified by the German Cancer Society 2015].

Authors:  J Fichtner; C Kowalski; S Wesselmann; P Albers
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

2.  [Minutes of the meeting of the Working Group on Uropathology].

Authors:  A Hartmann; R Knüchel-Clarke
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

3.  [Oncological healthcare research in urology - perspectives].

Authors:  J Bruns; C Kowalski
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

4.  The Treatment of Localized Prostate Cancer in Everyday Practice in Germany.

Authors:  Jan Herden; Lena Ansmann; Nicole Ernstmann; Dietrich Schnell; Lotharh Weißbac
Journal:  Dtsch Arztebl Int       Date:  2016-05-13       Impact factor: 5.594

5.  [The HAROW study: an example of outcomes research: a prospective, non-interventional study comparing treatment options in localized prostate cancer].

Authors:  J Herden; N Ernstmann; D Schnell; L Weißbach
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

6.  [Objective grading of prostate carcinoma based on fractal dimensions: Gleason 3 + 4= 7a ≠ Gleason 4 + 3 =7b].

Authors:  P Waliszewski; F Wagenlehner; S Kribus; W Schafhauser; W Weidner; S Gattenlöhner
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

7.  The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.

Authors:  Florian Koerber; Raphaela Waidelich; Björn Stollenwerk; Wolf Rogowski
Journal:  BMC Health Serv Res       Date:  2014-04-10       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.